| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 45,575,000 | 46,606,000 | 47,637,000 | 50,739,000 | 44,081,000 |
| Sales Growth | -2.21% | -2.16% | -6.11% | +15.10% | +6.48% |
| Net Income | -3,620,000 | -2,552,000 | -2,941,000 | 4,150,000 | 1,000,000 |
| Net Income Growth | -41.85% | +13.23% | -170.87% | +315.00% | +109.53% |
Bayer Ag (BAYN.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (39% of total sales in 2024) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (49% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
Fiscal Year End Date: 12/31